Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Paclitaxel and Pegylated Liposomal Doxorubicin in Recurrent Head and Neck Cancer: Clinical and Unexpected Pharmacokinetic Interactions

MARIO AIROLDI, LUIGI CATTEL, PAOLA MILLA, FULVIA PEDANI, MASSIMILIANO GARZARO and FRANCO DOSIO
Anticancer Research July 2008, 28 (4C) 2519-2527;
MARIO AIROLDI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: airoldim@yahoo.com
LUIGI CATTEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PAOLA MILLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FULVIA PEDANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASSIMILIANO GARZARO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCO DOSIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The combination of paclitaxel (PTX) with pegylated liposomal doxorubicin (PLD) is an interesting treatment for recurrent head and neck cancer. The pharmacokinetic behavior may depend on the interval between the intravenous administration of the two drugs. This study evaluates the clinical efficacy, toxicity and any possible interval-dependent pharmacokinetic interactions. Patients and Methods: Thirty patients were randomized to receive 80 mg/m2 PTX weekly and 12.5 mg/m2 PLD every two weeks at administration intervals of 0, 1, 3, 12 or 24 hours. Blood sampling was performed at day 1 and 15 and pharmacokinetics of PTX, PLD and Cremophor EL were evaluated by non-compartmental analysis. Results: Neutropenia was the most frequent side-effect (100% of patients; 30% grade 3-4). Hand-foot syndrome was severe in only 3% of patients. Overall response rate was 30%, with 3% complete responses and 27% partial responses. Stable disease and progression were 43% and 27%, respectively. Median response duration and overall median survival were 5.5 and 10 months respectively. Co-administration of PLD markedly reduced Cmax and the area under the curve (AUC), and increased PTX clearance. The differences in the PTX AUC and clearance between the 0 h and the 24 h experimental arms were statistically significant. Conclusion: The PTX/PLD combination plays a palliative role (clinical benefit in 73% of patients) and has good tolerability. The PTX pharmacokinetic profile was unexpectedly affected by different administration time intervals; in the 0 h arm the AUC was reduced to one fourth, therefore a schedule with PTX on day one, PLD on day two may be preferred.

  • Head and neck cancer
  • chemotherapy
  • Doxil
  • Caelyx
  • Taxol
  • pharmacokinetics

Footnotes

  • Received February 27, 2008.
  • Revision received June 2, 2008.
  • Accepted June 3, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Paclitaxel and Pegylated Liposomal Doxorubicin in Recurrent Head and Neck Cancer: Clinical and Unexpected Pharmacokinetic Interactions
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Paclitaxel and Pegylated Liposomal Doxorubicin in Recurrent Head and Neck Cancer: Clinical and Unexpected Pharmacokinetic Interactions
MARIO AIROLDI, LUIGI CATTEL, PAOLA MILLA, FULVIA PEDANI, MASSIMILIANO GARZARO, FRANCO DOSIO
Anticancer Research Jul 2008, 28 (4C) 2519-2527;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Paclitaxel and Pegylated Liposomal Doxorubicin in Recurrent Head and Neck Cancer: Clinical and Unexpected Pharmacokinetic Interactions
MARIO AIROLDI, LUIGI CATTEL, PAOLA MILLA, FULVIA PEDANI, MASSIMILIANO GARZARO, FRANCO DOSIO
Anticancer Research Jul 2008, 28 (4C) 2519-2527;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Radiomics for Growth Prediction of Vestibular Schwannomas in Neurofibromatosis Type 2
  • Chemotherapy-induced Moderate to Severe Peripheral Neuropathy in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
  • Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire